Combining GroupAdvance’s in-depth knowledge of the ophthalmic industry, global network of thought leaders in the field, and practical expertise relating to intellectual property management, GroupAdvance provides customized services relating to R&D assessment and assessing technology in ophthalmology as it relates to mergers and acquisitions.
GroupAdvance can take a lead role or supporting function relating to the needs and demands of the client. From a straightforward request of a Freedom to Operate report based on an idea or patent application or rather a more complex mandate of leading a research and development workstream through a due diligence, GroupAdvance supports the client’s interest and delivers what is required on time. The consultants at GroupAdvance strongly believes that there is no excuse to miss a deadline.
GroupAdvance also strives to understand the overall goals and interests of the client to best serve the client. In other words, GroupAdvance wants more than just to deliver, GroupAdvance wants to support the client. So, even with a simplistic demand, GroupAdvance is able to tailor and deliver the work and services provided to help achieve the client’s overall goal(s). While assessing technology in ophthalmology, GroupAdvance provides all deliverables in electronic format for easy referencing, and GroupAdvance is available to support the client in case of later questions after the mandate has been fulfilled.
GroupAdvance also challenges the deliverables and direction of the project if the consultant deems that the results are not in the interest of the client. In the case that unfavorable results are found or concluded, GroupAdvance will support the client to either navigate around the situation or address the problem directly. Damage control is never a position that a company would want to have, but in the case the client finds him or herself in the position, GroupAdvance will strive to find the quickest and least damaging options with the client’s interest in mind.
CXL at the slit lamp may provide access to all. Cataract & Refractive Surgery Today Europe April 2017: ELZA member and EMAGine CEO Nikki Hafezi describes the technique of CXL at the slit lamp may help simplify CXL procedures for both keratoconus and corneal
ESCRS (European Society for Cataract and Refractive Surgery) Copenhagen The Geneva University Spin-off company EMAGine will present the C-Eye device. This mobile cross-linking technology will allow for slit lamp cross-linking (CXL and PACK-CXL) treatments. See a video of the device
Ocular Surgery News Europe. Editorial on the OSN Roundtable discussion, written by Farhad and Nikki Hafezi from ELZA in Switzerland. Read the editorial here. Read the roundtable discussion here.
Gubelstrasse 12
6300 Zug
Switzerland
Tel: +41 41 560 91 91
Fax: +41 41 560 91 99
info@groupadvance.com
Designed by Mad Lemmings
